EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

No news is bad news for Tocagen

Tocagen said Tuesday its brain cancer trial has not been able to show so far that a combination therapy of experimental agents Toca 511 and Toca FC extended survi...
Continue Reading →
Europe

Depression: Esketamine trial leaves ‘more questions than answers’

A phase 3 clinical trial testing esketamine nasal spray in the treatment of severe depression found the spray mostly safe and effective. The findings led to the rece...
Continue Reading →
Europe

BioCryst meets late-stage study goal, but falls short of competition

A small North Carolina-based biotech got a lot smaller Tuesday, despite the company announcing its rare disease drug met the primary goal of a pivotal Phase 3 stu...
Continue Reading →
Europe

Long-term heart data reassures for Medicines Co.

The Medicines Company on Saturday released data from a long-term safety study of its experimental cholesterol-lowering drug inclisiran in heart disease patients, ...
Continue Reading →
Europe

Array’s ‘extremely compelling’ new colon cancer data spark blockbuster talk

Array's Mektovi and Braftovi, when combined with Erbitux, produced a survival benefit in patients with BRAF-positive colon cancer. (Array BioPharma) The news tha...
Continue Reading →
Europe

Benralizumab not effective reducing exacerbations in moderate to very severe COPD

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, accord...
Continue Reading →
Europe

Lilly drug scores in Phase 2 Crohn’s study

An experimental immunology drug from Eli Lilly has scored positive data in a mid-stage study of Crohn's disease patients.The study enrolled 180 participants, who rec...
Continue Reading →
Europe

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following managemen...
Continue Reading →
Europe

AstraZeneca blood cancer drug hits study goal early

A Phase 3 trial testing AstraZeneca's Calquence in previously treated chronic lymphocytic leukemia will be stopped early, after an interim analysis found patients...
Continue Reading →
Europe

Bristol-Myers’ Opdivo fails in Phase 3 glioblastoma test

Bristol-Myers Squibb said a late-stage Opdivo study showed the medicine failed to prolong overall survival in patients with a type of newly diagnosed brain cancer.Th...
Continue Reading →
Catalyst: 12th January 2026
Quotient